Form 4: Acrivon Therapeutics CFO Acquires Shares

Acrivon Therapeutics, Inc. Chief Financial Officer, Adam D. Levy, acquired 46,167 restricted stock units on May 18, 2026.

Summary

• Adam D. Levy, Chief Financial Officer of Acrivon Therapeutics, Inc., acquired 46,167 restricted stock units (RSUs) on May 18, 2026.
• These RSUs represent a contingent right to receive one share of the Issuer's Common Stock per RSU.
• Vesting of these RSUs is scheduled, with 16.67% vesting on November 18, 2026, and the remainder vesting in 10 subsequent equal quarterly installments, contingent on continued service.
• Following this transaction, Mr. Levy beneficially owns 67,150 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents an insider acquiring equity, but the nature of RSUs and the lack of purchase price suggest a standard compensation/incentive grant rather than a conviction-based investment.

Positives

• The Chief Financial Officer's acquisition of RSUs may signal confidence in the company's future prospects.
• The acquisition is structured as RSUs, which are performance-based and tied to continued service, aligning management incentives with long-term company success.

Negatives

• The filing does not provide details on the acquisition price, only that the value was $0 at the time of acquisition, suggesting these were granted rather than purchased.
• The vesting schedule indicates a phased release of shares, meaning the full benefit is not immediate.

Risks

• The vesting of RSUs is subject to the Reporting Person's continuous service, meaning any departure before vesting dates could result in forfeiture of these units.
• The value of the RSUs is tied to the performance of Acrivon Therapeutics, Inc.'s common stock, which is subject to market volatility and company-specific risks.

Future Outlook

The future outlook for the acquired RSUs is dependent on the continued service of Adam D. Levy and the performance of Acrivon Therapeutics, Inc.'s common stock, with a phased vesting schedule extending beyond November 18, 2026.

Industry Context

StockSavvy.ai notes that insider transactions, particularly the acquisition of equity by C-suite executives like CFOs, are often scrutinized by investors as potential indicators of management's confidence in the company's future performance within the biotechnology sector.

Stakeholder Impact

• Shareholders: May view the CFO's acquisition of RSUs as a positive sign of commitment, though the impact is indirect as these are granted shares.
• Employees: The vesting schedule for RSUs is a common incentive, potentially motivating continued employee retention and performance.
• Management: Aligns the CFO's interests with shareholders through equity-based compensation tied to service and company performance.

Next Steps

• Continued service by Adam D. Levy through the vesting dates to receive shares.
• Monitoring of Acrivon Therapeutics, Inc.'s stock performance and corporate developments.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, Insider Transaction, Restricted Stock Units, RSU, Adam D. Levy, Chief Financial Officer, Securities Ownership, Vesting Schedule